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Dense glycosylation on the HIV-1 envelope glycoprotein hampers the induction of broadly neutral-
izing antibodies against HIV-1. Zhou et al. remove key glycans to unmask sites of vulnerability and
enable the induction of neutralizing antibodies.The HIV-1 envelope glycoprotein is
decorated with a dense array of glycans
that masks nearly the entire surface
of the infectious envelope, posing a
significant barrier to antibodies that aim
to target sites of neutralization vulnera-
bility. Thus, the HIV-1 envelope glycan
shield has been regarded as a signifi-
cant impediment to the induction of pro-
tective antibody responses (Wei et al.,
2003). However, emerging antibody
isolation technologies linked to sophisti-
cated structural analyses have shown
that viral glycans are tolerated near
broadly neutralizing antibody epitopes
and commonly form part of the epitopes
themselves (McCoy and Burton, 2017),
arguing that antibodies are able to work
around the glycan shield to access the
viral protein surface. Moreover, while
broadly neutralizing antibodies recog-
nizing glycans alone are rare, glycan-
dependent HIV-1 neutralizing antibodies
that target a combination of glycans
and the underlying protein (glycopeptide)
are not uncommon. In fact, these
glycopeptide-targeting antibodies are
frequently generated during natural
infection (Cohen et al., 2015), suggesting
that an HIV-1 vaccine able to drive hu-
moral immunity that may overcome or
tolerate the glycan shield may success-
fully induce broadly neutralizing anti-
bodies. However, the development of
broadly neutralizing antibodies during
infection takes years, often requiring
extensive affinity maturation and unusual
antibody modifications to reach the
HIV-1 envelope between glycans. Thus,
approaches are urgently needed to
accelerate this process.This is an open access arIn this issue of Cell Reports, Zhou et al.
(2017) explore a new immunization strat-
egy aimed at initiating the evolution of
broadly neutralizing antibodies to protein
epitopes within key sites of viral vulnera-
bility that may then evolve with later
boosts to tolerate glycans. Specifically,
they attempt to facilitate the induction of
humoral immunity to the CD4 receptor
binding site by using native-like soluble
envelope protein immunogens with dele-
tions of key blocking glycans surrounding
the CD4 binding site, enabling easier ac-
cess for B cell receptors to the underlying
protein epitope (Figure 1). This strategy
builds on the observation that glycan
‘‘holes’’ in the HIV-1 envelope trimer pro-
tein allow antibodies to evolve to exposed
protein surfaces, providing a means to
focus the immune response upon vacci-
nation (McCoy et al., 2016). Along the
same lines, removal of a single glycan
proximal to the CD4 binding site enabled
the binding and activation of CD4 binding
site-specific antibody B cell receptor pre-
cursors that were otherwise blocked by
the glycan (McGuire et al., 2013).
To rationally design an optimal CD4
binding site glycan ‘‘hole,’’ Zhou et al.
(2017) model the dynamics of the HIV-1
glycan shield on the crystal structure of
native-like soluble envelopes. They then
generate immunogens of HIV-1 clade A,
B, and C with three to four glycan dele-
tions based on those most likely to
interfere with access of the CD4 binding
site-specific broadly neutralizing anti-
body, VRC01. The optimized immuno-
gens maintain a desired prefusion-closed
state, as demonstrated by negative stain
EM. They also exhibit enhanced bindingticle under the CC BY-NC-ND license (http://crto CD4 binding site-specific broadly
neutralizing antibodies, highlighting the
impact of glycan removal on improved
CD4 epitope antigenicity. Guinea pigs
and rhesus macaques vaccinated with
the glycan-optimized mutants generate
neutralizing responses against the CD4
binding site of autologous glycan-opti-
mized mutants, but these responses are
unable to neutralize wild-type glycosy-
lated viral variants. However, the HIV-1
clade C CH505 glycan-optimized variant
can induce a CD4 binding site-specific
serum response with substantial neutrali-
zation breadth against glycan-deleted
envelope proteins in guinea pigs and rhe-
sus macaques. The neutralizing breadth
induced by this immunogen can be further
increased following vaccination with a
mix of glycan-deleted immunogens from
different viral clades. Finally, to determine
if the size of the access surface area
around a vulnerable site plays an essential
role in immune focusing, they immunize
with glycan-depleted immunogens where
only single deleted glycans were reintro-
duced. The efficiency of vaccine-induced
serum neutralization is directly and pro-
portionally linkedwith surface area acces-
sibility, highlighting the critical need to
design holes in a rational and strategic
manner.
Unlike previous studies, Zhou et al.
(2017) integrate molecular dynamics
modeling to design optimal glycan
‘‘holes’’ within the HIV-1 glycan shield to
generate their glycan-optimized candi-
date immunogens. Thus, the authors
are able to both exploit the blocking
effects of the glycan shield to prevent
the induction of non-neutralizing antibodyCell Reports 19, April 25, 2017 ª 2017 669
eativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. The HIV-1 Envelope Is Covered by a Dense Array of Glycans—Termed the Glycan
‘‘Shield’’—which Block Antibody Access to Sites of Vulnerability, Preventing the Induction of
Broadly Neutralizing Antibodies
Zhou et al. (2017) used molecular dynamics modeling to identify a specific set of glycans that, once
removed, created a glycan ‘‘hole’’ that improved immunogen antigenicity and resulted in the induction of
neutralizing antibody responses.responses and exploit glycans to focus
the immune response to a key site
of vulnerability. This strategy enables
modeling of the consequences of glycan
deletions on both neighboring and distant
glycan mobility and interactions that can
both directly or indirectly impact antibody
access and antigenicity (Behrens et al.,
2016), providing critical insights into the
link between surface area accessibility
and neutralization. While others have
aimed to developminimal scaffolded anti-
gens that mimic the CD4 binding site (Bri-
ney et al., 2016), Zhou et al. (2017) offer a
simple solution to focus the initial humoral
immune response to sites of neutralizing
vulnerability via the simple exploitation of
the glycan shield. The data suggest that
the glycan-deleted immunogens may be670 Cell Reports 19, April 25, 2017suitable as the first antigen in a sequential
HIV-1 vaccine strategy, aimed at kick
starting the humoral immune response,
which may be followed by fully glycosy-
lated, otherwise-engineered immunogens
or even combinations of immunogens
aimed at broadening the response.
However, the authors leave room for
speculation related to the utility of this
methodological approach to focus the
immune response to other sites on the
viral envelope, as well as related to
the overall comparability of this approach
to the minimal antigen-design strategies.
In summary, Zhou et al. (2017) demon-
strate that a targeted CD4 binding site-
specific neutralizing antibody response
can be induced via the design of immuno-
gens that permit unhindered access to thetargeted epitope. Thus, Zhou et al. (2017)
describe a novel class of immunogens
that provide an exciting straight-forward
solution to focus the immune response
to key sites of viral vulnerability.REFERENCES
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